Prediagnostic serum inflammatory markers in relation to breast cancer risk, severity at diagnosis and survival in breast cancer patients

Carcinogenesis

Volumn 36, Issue 10, 2015, Pages 1121-1128

  Wulaningsih, Wahyu ^a   Holmberg, Lars ^a,b,c   Garmo, Hans ^a,c   Malmstrom, Håkan ^d   Lambe, Mats ^c,d   Hammar, Niklas ^d,e   Walldius, Göran ^d   Jungner, Ingmar ^d   Van Hemelrijck, Mieke ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c Regional Cancer Centre   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; ESTROGEN RECEPTOR; HAPTOGLOBIN; TUMOR MARKER; PROGESTERONE RECEPTOR;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD BIOCHEMISTRY; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CAUSE OF DEATH; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; LEUKOCYTE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SWEDISH CITIZEN; BLOOD; BREAST NEOPLASMS; CANCER STAGING; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RISK FACTOR;

ADULT; BIOMARKERS, TUMOR; BREAST NEOPLASMS; C-REACTIVE PROTEIN; FEMALE; HUMANS; INFLAMMATION; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS;

EID: 84943783258     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgv096     Document Type: Article

References (47)

1. Hanahan, D. et al. (2011) Hallmarks of cancer: the next generation. Cell, 144, 646-674.
2. Ali, H.R. et al. (2014) Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann. Oncol., 25, 1536-1543.
3. Gu-Trantien, C. et al. (2013) CD4+ follicular helper T cell infiltration predicts breast cancer survival. J. Clin. Invest., 123, 2873-2892.
4. Loi, S. et al. (2013) Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J. Clin. Oncol., 31, 860-867.
5. Prizment, A.E. et al. (2013) Plasma C-reactive protein, genetic risk score, and risk of common cancers in the Atherosclerosis Risk in Communities study. Cancer Causes Control, 24, 2077-2087.
6. Il'yasova, D. et al. (2005) Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol. Biomarkers Prev., 14, 2413-2418.
7. Siemes, C. et al. (2006) C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J. Clin. Oncol., 24, 5216-5222.
8. Touvier, M. et al. (2013) Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: a nested case-control study. Am. J. Epidemiol., 177, 3-13.
9. Gaudet, M.M. et al. (2013) Obesity-related markers and breast cancer in CPS-II Nutrition Cohort. Int. J. Mol. Epidemiol. Genet., 4, 156-166.
10. Van Hemelrijck, M. et al. (2011) Association between levels of C-reactive protein and leukocytes and cancer: three repeated measurements in the Swedish AMORIS study. Cancer Epidemiol. Biomarkers Prev., 20, 428-437.
11. Guo, Y.Z. et al. (2013) Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies. Asian Pac. J. Cancer Prev., 14, 243-248.
12. Heikkilä, K. et al. (2009) Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control, 20, 15-26.
13. Aleksandrova, K. et al. (2014) Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer. Hepatology, 60, 858-871.
14. Kaysen, G.A. et al. (2000) The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. The HEMO Study Group. Kidney Int., 58, 346-352.
15. Holme, I. et al. (2010) Inflammatory markers, lipoprotein components and risk of major cardiovascular events in 65,005 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). Atherosclerosis, 213, 299-305.
16. Register BCQ. Regional Oncologic Centre in the Uppsala/örebro Region, Sweden.
17. Goldhirsch, A. et al. (2001) Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J. Clin. Oncol., 19, 3817-3827.
18. Wilkins, J. et al. (1998) Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. Clin. Chem., 44(6 Pt 1), 1358-1361.
19. Van Hemelrijck, M. et al. (2011) Risk of prostate cancer is not associated with levels of C-reactive protein and other commonly used markers of inflammation. Int. J. Cancer, 129, 1485-1492.
20. Gaur, A. et al. (2013) Iron metabolism and risk of cancer in the Swedish AMORIS study. Cancer Causes Control, 24, 1393-1402.
21. Visser, M. et al. (1999) Elevated C-reactive protein levels in overweight and obese adults. JAMA, 282, 2131-2135.
22. Renehan, A.G. et al. (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet, 371, 569-578.
23. Meliconi, R. et al. (1988) Acute phase proteins in chronic and malignant liver diseases. Liver, 8, 65-74.
24. Borlak, J. et al. (2013) Serum acute phase reactants hallmark healthy individuals at risk for acetaminophen-induced liver injury. Genome Med., 5, 86.
25. Doyle, M.K. et al. (2013) Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial. Rheumatology (Oxford), 52, 1214-1219.
26. Karin, M. (2006) Nuclear factor-kappaB in cancer development and progression. Nature, 441, 431-436.
27. Yu, H. et al. (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer, 9, 798-809.
28. Prasad, S. et al. (2010) NF-kappaB and cancer: how intimate is this relationship. Mol. Cell. Biochem., 336, 25-37.
29. Resemann, H.K. et al. (2014) The Stat3 paradox: a killer and an oncogene. Mol. Cell. Endocrinol., 382, 603-611.
30. Yu, J. et al. (2014) Noncanonical NF-κB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer. J. Immunol., 193, 2574-2586.
31. Barclay, J.L. et al. (2009) SOCS3 as a tumor suppressor in breast cancer cells, and its regulation by PRL. Int. J. Cancer, 124, 1756-1766.
32. Nishikawa, T. et al. (2008) Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1 alpha is essential for cytokinedriven C-reactive protein gene expression. J. Immunol., 180, 3492-3501.
33. Agrawal, A. et al. (2003) Overexpressed nuclear factor-κB can participate in endogenous C-reactive protein induction, and enhances the effects of C/EBPß and signal transducer and. Immunology, 65, 1-9.
34. Uskokovic, A. et al. (2012) STAT3/NF-κB interactions determine the level of haptoglobin expression in male rats exposed to dietary restriction and/or acute phase stimuli. Mol. Biol. Rep., 39, 167-176.
35. Zhang, S.M. et al. (2007) C-reactive protein and risk of breast cancer. J. Natl. Cancer Inst., 99, 890-894.
36. Allin, K.H. et al. (2009) Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J. Clin. Oncol., 27, 2217-2224.
37. Dossus, L. et al. (2014) C-reactive protein and postmenopausal breast cancer risk: results from the E3N cohort study. Cancer Causes Control, 25, 533-539.
38. Arendt, L.M. et al. (2013) Obesity promotes breast cancer by CCL2-mediated macrophage recruitment and angiogenesis. Cancer Res., 73, 6080-6093.
39. Skibinski, C.G. et al. (2013) Proteomic changes induced by effective chemopreventive ratios of n-3:n-6 fatty acids and tamoxifen against MNUinduced mammary cancer in the rat. Cancer Prev. Res. (Phila)., 6, 979-988.
40. Gonçalves, A. et al. (2006) Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene, 25, 981-989.
41. Kailajärvi, M. et al. (2000) Early effects of adjuvant tamoxifen therapy on serum hormones, proteins and lipids. Anticancer Res., 20(2B), 1323-1327.
42. Dowling, P. et al. (2012) Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. Int. J. Cancer, 131, 911-923.
43. Villaseñor, A. et al. (2014) Postdiagnosis C-reactive protein and breast cancer survivorship: findings from the WHEL study. Cancer Epidemiol. Biomarkers Prev., 23, 189-199.
44. Pierce, B.L. et al. (2009) Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J. Clin. Oncol., 27, 3437-3444.
45. Sicking, I. et al. (2014) Prognostic influence of pre-operative C-reactive protein in node-negative breast cancer patients. PLoS One, 9, e111306.
46. Alkhateeb, A.A. et al. (2012) Elevation in inflammatory serum biomarkers predicts response to trastuzumab-containing therapy. PLoS One, 7, e51379.
47. Kaptoge, S. et al. (2010) C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet, 375, 132-140.